首页> 外文期刊>Seminars in Nuclear Medicine >Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy.
【24h】

Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy.

机译:橡树岭国家实验室的钨188 / r 188发生器在制备用于跨动脉肝癌治疗的188 188 HDD /碘油复合物中的用途。

获取原文
获取原文并翻译 | 示例
       

摘要

This work describes the installation, use, and quality control (QC) of the alumina-based tungsten-188 ((188)W)/rhenium-188 ((188)Re) generators provided by the Oak Ridge National Laboratory (ORNL). In addition, methods used for concentration of the (188)Re-perrhenate bolus and preparation of (188)Re-labeled HDD (4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol) for trans-arterial administration for therapy of nonresectable liver cancer also are described. The (188)W/(188)Re generator has a long useful shelf-life of several months and is a convenient on-site (188)Re production system. (188)Re has excellent therapeutic and imaging properties (T(1/2) 16.9 hours; E(betamax) 2.12 MeV; 155-keV gamma ray, 15%) and is cost effectively obtained on demand by saline elution of the generator. The clinical efficacy of a variety of (188)Re-labeled agents has been demonstrated for several therapeutic applications. Because of the favorable physical properties of (188)Re, several (188)Re-labeled agents are being developed and evaluated for the treatment of nonresectable/refractory liver cancer. (188)Re-labeled HDD has been the most widely studied of these agents for this application and has been introduced into clinical trials at a number of institutions. The trans-arterial administration of (188)Re-labeled agents for treatment of inoperable liver cancer requires use of high-level (1-2 Ci) (188)W/(188)Re generators. The handling of such high levels of (188)Re imposes radiological precautions normally not encountered in a radiopharmacy and adequate care and ALARA (ie, "As Low As Reasonably Achievable") principles must be followed. The ORNL generator provides consistently high (188)Re yields (>75%) and low (188)W parent breakthrough (<10(-3)%) over an extended shelf-life of several months. However, the high elution volumes (20-40 mL for 1-2 Ci generators) can require concentration of the (188)Re bolus by postelution passage through silver cation chloride trapping columns used in the cost-effective tandem cation/anion column system. The silver column removes the high levels of chloride anion as insoluble AgCl, thus allowing subsequent specific trapping of the perrhenate anion on the small (QMA SeaPak) anion column. This method permits subsequent elution of (188)Re-perrhenate with a small volume of saline, providing a very high activity-concentration solution. Because the (188)Re-specific volume-activity concentration continually decreases with time, the tandem system is especially effective method for extending the useful generator shelf-life. Low elution flow rates (<1 mL/min) minimize any high back pressure which may be encountered during generator/tandem column elution when using tightly packed, small-particle-size commercial columns. In-house preparation of silver cation columns is recommended since the chloride trapping capacity is essentially unlimited, it is inexpensive and not limited in availability to any one supplier, and back pressure can be eliminated by the use of larger particles. Methods for the preparation of (188)Re-HDD have been optimized and this agent can be obtained in high yield (80%).
机译:这项工作描述了橡树岭国家实验室(ORNL)提供的氧化铝基钨188((188)W)/ hen 188((188)Re)发生器的安装,使用和质量控制(QC)。此外,用于浓缩(188)Re-高r酸盐药丸和制备(188)Re-标记HDD(4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10)的方法还描述了用于经动脉给药以治疗不可切除的肝癌的β-癸硫醇)。 (188)W /(188)Re发生器具有几个月的长使用寿命,是一种方便的现场(188)Re生产系统。 (188)Re具有出色的治疗和成像性能(T(1/2)16.9小时; E(betamax)2.12 MeV; 155-keV伽马射线,15%),并且通过发生器的盐水洗脱可按需经济地获得。多种(188)Re标记药物的临床疗效已在多种治疗应用中得到证实。由于(188)Re的良好物理特性,正在开发和评估几种(188)Re标记的药物,用于治疗不可切除/难治性肝癌。 (188)对于这种应用,重新标记的HDD已在这些药物中得到了最广泛的研究,并已被引入许多机构的临床试验中。 (188)Re标记药物的经动脉给药治疗无法手术的肝癌需要使用高水平的(1-2 Ci)(188)W /(188)Re产生剂。处理如此高水平的(188)Re会施加放射预防措施,通常在放射药学和适当护理中是没有的,因此必须遵循ALARA(即“合理可行的最低标准”)原则。 ORNL发生器在几个月的延长保质期内始终提供高(188)Re产率(> 75%)和低(188)W母体突破(<10(-3)%)。但是,高洗脱体积(对于1-2 Ci生成器而言为20-40 mL)可能需要通过高效洗脱的串联阳离子/阴离子柱系统中使用的银阳离子氯化物捕集柱的后洗脱来浓缩(188)Re推注。银柱可去除高水平的氯离子(不溶性AgCl),因此可将高r酸根阴离子随后截留在小(QMA SeaPak)阴离子柱上。该方法允许用少量盐水随后洗脱(188)Re-高r酸盐,从而提供了很高的活性浓度溶液。因为(188)Re-比体积活度浓度随时间连续降低,所以串联系统是延长有用的发生器保质期的特别有效的方法。低洗脱流速(<1 mL / min)使使用紧密堆积的小粒径商业色谱柱时在发生器/串联色谱柱洗脱过程中可能遇到的任何高背压最小化。推荐内部制备银阳离子柱,因为氯离子的捕集能力实际上是无限的,它的价格便宜且不受任何供应商的限制,并且可以通过使用较大的颗粒来消除背压。优化了制备(188)Re-HDD的方法,可以高收率(80%)获得该试剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号